Evaluation of Roles of MicroRNA-21 and MicroRNA-18a in Esophageal Squamous Cell Carcinoma and Comparison of Their Changes in Expression Post-Chemoradiotherapy

Overview

Journal Gastroenterology Res

Specialty Gastroenterology

Date 2020 Jul 14

PMID 32655727

Citations 1

Authors

Mohd Talha Noor

Nivesh Seehra

Jitendra Rajput

Rajeev Sharma

Bhagwan Singh Thakur

Affiliations

Soon will be listed here.

Abstract

Background: A number of circulating microRNAs (miRNAs) have been reported to be highly expressed in several cancers; whether their expression is associated with clinicopathological factors and prognosis in patients of esophageal squamous cell carcinoma (ESCC) is still under investigation. Although studies have demonstrated their overexpression in tissues of ESCC, there are limited data for circulating miRNAs. Aim of this study was to evaluate the expressions of miRNA-21 and miRNA-18a in patients of ESCC and the effect of chemoradiotherapy (CRT) on expression of these miRNAs.

Methods: This was a case-control study conducted from September 2014 to December 2015 at Sri Aurobindo Medical College and Postgraduate Institute, Indore, India. We compared the expression of miRNA-21 and miRNA-18a in 30 ESCC patients and 30 healthy controls using TaqMan probe-based quantitative real-time polymerase chain reaction (qRT-PCR) and changes in the expression in 16 patients of ESCC, who completed CRT.

Results: Both miRNA-21 and miRNA-18a had significantly higher levels of expression in ESCC patients than healthy controls (95% confidence interval (CI): 5.73 - 34.79; P < 0.002 and 95% CI: 3,361.36 - 6,744.23; P < 0.001), respectively. Receiver operating characteristic (ROC) curve analysis showed that combination of serum miRNA-18a and miRNA-21 overexpression could efficiently distinguish patients of ESCC from healthy controls. The miRNA-21 expression positively correlated with tumor invasion (P < 0.004), lymphatic metastasis (P < 0.011), distant metastasis (P < 0.038), and tumor stage (P < 0.001); however, there was no such association observed with miRNA-18a. In the treatment phase (post-CRT), a significant reduction (P < 0.001) was observed in both miRNAs (73.4% in miRNA-18a and 81.02% in miRNA-21).

Conclusions: Both miRNA-21 and miRNA-18a were highly overexpressed in patients of ESCC and their expressions changed significantly with CRT. These miRNAs may be useful tools for the diagnosis and assessment of treatment response in ESCC patients. Further studies will be needed to validate these findings using large number of patients.

Citing Articles

MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma.

Wei Q, Jin F, Wang Z, Li B, Cao W, Sun Z World J Gastroenterol. 2024; 30(11):1497-1523.

PMID: 38617454 PMC: 11008420. DOI: 10.3748/wjg.v30.i11.1497.

References

Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S . Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2012; 106(2):188-92. DOI: 10.1002/jso.23064. View

Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K . Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg. 2004; 28(7):680-5. DOI: 10.1007/s00268-004-6865-y. View

Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A . Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013; 108(9):1822-9. PMC: 3658511. DOI: 10.1038/bjc.2013.148. View

Hiyama T, Yoshihara M, Tanaka S, Chayama K . Genetic polymorphisms and esophageal cancer risk. Int J Cancer. 2007; 121(8):1643-58. DOI: 10.1002/ijc.23044. View

Ruol A, Castoro C, Portale G, Cavallin F, Sileni V, Cagol M . Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg. 2009; 144(3):247-54. DOI: 10.1001/archsurg.2008.574. View

Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M . Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2012; 119(6):1159-67. DOI: 10.1002/cncr.27895. View

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N . Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2010; 81(3):684-90. DOI: 10.1016/j.ijrobp.2010.06.033. View

Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H . Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus. 2011; 24(7):523-30. DOI: 10.1111/j.1442-2050.2011.01177.x. View

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

10.

Li L, Guo Z, Wang J, Mao Y, Gao Q . Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012; 57(11):2910-6. DOI: 10.1007/s10620-012-2317-y. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Coia L, Myerson R, Tepper J . Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 1995; 31(5):1213-36. DOI: 10.1016/0360-3016(94)00419-L. View

13.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

14.

Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Mansour Samaei N, Naghshvar F . Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. PLoS One. 2013; 8(9):e73009. PMC: 3769386. DOI: 10.1371/journal.pone.0073009. View

15.

Lim J, Truong P, Berthelet E, Pai H, Joe H, Wai E . Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003; 57(5):1328-35. DOI: 10.1016/s0360-3016(03)00751-x. View

16.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

17.

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

18.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View